Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> = 70 years.~* Performance status \< = 2 (WHO criteria)~* Life expectancy \> 3months~* A patient with solid tumor locally advanced or metastatic~* Indication of systemic anticancer treatment : oral or IV chemotherapy, endocrine therapy, target therapy or immunotherapy~* MMS-orientation ≥ 7 (geriatric Mini Mental State face-to-face questionnaire)~* Able to swallow and retain oral treatment~* Patient who signed the participation consent before entering the trial~* Patient able to read, write and understand French.~* Affiliation to the french social security scheme (or beneficiary of such a scheme) under the terms of the law of 9 August 2004.~Exclusion Criteria:~* Haematological cancers~* Renal failure or hepatic failure~* Auto-immune disease~* Diagnosed neurodegenerative diseases~* Unability to fill out questionnaires~* melatonin treatment ongoing or completed for less than 3 months~* Treatment with an investigational drug, participation to another therapeutic clinical trial within \<30 days~* Hypersensitivity to melatonin or any of the excipients~* Current Treatment with fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, estrogen~* A history of known or suspected excessive alcohol use.~* Patient refusing to participate and / or unable to give informed consent~* Patient unable to complete the questionnaires even with the help of a relative or a nurse~* Patient does not have the capacity to comply with the study requirements~* Patient deprived of liberty by a court or administrative.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group Melatonin (Type: EXPERIMENTAL): standard anticancer treatment + 3-month of melatonin supplementation
- Group Placebo (Type: PLACEBO_COMPARATOR): standard anticancer treatment + placebo (3 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).